Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
Evolent Health Inc (NYSE: EVH) closed the day trading at $4.0 down -4.76% from the previous closing price of $4.2. In other words, the price has decreased by -$4.76 from its previous closing price. On the day, 2.47 million shares were traded. EVH stock price reached its highest trading level at $4.23 during the session, while it also had its lowest trading level at $3.95.
Ratios:
For a better understanding of EVH, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.33 and its Current Ratio is at 1.33. In the meantime, Its Debt-to-Equity ratio is 1.29 whereas as Long-Term Debt/Eq ratio is at 1.26.
On November 13, 2025, BMO Capital Markets started tracking the stock assigning a Outperform rating and target price of $7. On January 10, 2025, Needham started tracking the stock assigning a Buy rating and target price of $15.Needham initiated its Buy rating on January 10, 2025, with a $15 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 18 ’25 when Springstubb Brendan B bought 10,000 shares for $3.82 per share. The transaction valued at 38,199 led to the insider holds 58,821 shares of the business.
Holder Diane bought 2,735 shares of EVH for $25,518 on Mar 06 ’25. The Director now owns 70,584 shares after completing the transaction at $9.33 per share. On Mar 06 ’25, another insider, McCarthy Daniel Joseph, who serves as the PRESIDENT of the company, bought 11,040 shares for $9.01 each. As a result, the insider paid 99,470 and bolstered with 389,004 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EVH now has a Market Capitalization of 463884544 and an Enterprise Value of 1412068480. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.22 while its Price-to-Book (P/B) ratio in mrq is 0.53. Its current Enterprise Value per Revenue stands at 0.687 whereas that against EBITDA is 17.687.
Stock Price History:
The Beta on a monthly basis for EVH is 0.27, which has changed by -0.6413322 over the last 52 weeks, in comparison to a change of 0.12607694 over the same period for the S&P500. Over the past 52 weeks, EVH has reached a high of $13.21, while it has fallen to a 52-week low of $3.49. The 50-Day Moving Average of the stock is -39.97%, while the 200-Day Moving Average is calculated to be -54.54%.
Shares Statistics:
Over the past 3-months, EVH traded about 3.50M shares per day on average, while over the past 10 days, EVH traded about 4950580 shares per day. A total of 111.59M shares are outstanding, with a floating share count of 102.96M. Insiders hold about 7.74% of the company’s shares, while institutions hold 117.99% stake in the company. Shares short for EVH as of 1763078400 were 18762717 with a Short Ratio of 5.36, compared to 1760486400 on 17620752. Therefore, it implies a Short% of Shares Outstanding of 18762717 and a Short% of Float of 17.03.
Earnings Estimates
Evolent Health Inc (EVH) is currently under the scrutiny of 12.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is $0.05, with high estimates of $0.17 and low estimates of -$0.04.
Analysts are recommending an EPS of between $0.13 and -$0.03 for the fiscal current year, implying an average EPS of $0.06. EPS for the following year is $0.3, with 9.0 analysts recommending between $0.78 and -$0.09.
Revenue Estimates
15 analysts predict $470.22M in revenue for. The current quarter. It ranges from a high estimate of $484.1M to a low estimate of $464.2M. As of. The current estimate, Evolent Health Inc’s year-ago sales were $646.54MFor the next quarter, 15 analysts are estimating revenue of $552.2M. There is a high estimate of $608.14M for the next quarter, whereas the lowest estimate is $510.91M.
A total of 14 analysts have provided revenue estimates for EVH’s current fiscal year. The highest revenue estimate was $1.89B, while the lowest revenue estimate was $1.87B, resulting in an average revenue estimate of $1.88B. In the same quarter a year ago, actual revenue was $2.55BBased on 11 analysts’ estimates, the company’s revenue will be $2.44B in the next fiscal year. The high estimate is $2.52B and the low estimate is $2.3B.
